



INDO-BANGLA PHARMACEUTICALS PLC.

Corporate Office:

Plot-183 (7th Floor), Block # B, Ahmed Akbar Sobhan Road,
Bashundhara R/A, Dhaka-1229.

Factory: 729, College Road, Barishal-8200.

PRICE SENSITIVE INFORMATION

This is for kind information that, the Board of Directors of Indo-Bangla Pharmaceuticals PLC (“Company”) in its meeting held on Thursday 29th January, 2026 at 4:00 p.m. at the corporate office, has approved the Un-Audited Financial Statements for the Second Quarter (Q2) period ended on 31th December, 2025.

The key financial highlights for the Second Quarter ended 31th December, 2025 are appended below:

Particulars	As at 31.12.2025	As at 30.06.2025
Net Asset Value (NAV) Per Share	Tk. 12.55	Tk. 12.53

Particulars	July to December 2025	July to December 2024	October to December 2025	October to December 2024
Earnings Per Share (EPS)	Tk. 0.02	Tk. (0.08)	Tk. 0.01	Tk. (0.05)
Net Operating Cash Flow Per Share (NOCFPS)	Tk. 0.02	Tk. 0.03	-	-

Reasons for Significant Deviation:

Sales revenue increased by 84.84% during the Second Quarter (October–December 2025), rising from Tk. 27,293,882 to Tk. 50,450,380 compared to the same period of the previous year, mainly due to higher sales volume, including execution of the first export shipment of medicine to Afghanistan under an existing export agreement, improved market demand, and better operational performance during the period.

Earnings Per Share (EPS) increasing from Tk. (0.05) to Tk. 0.01 compared to the same period of the previous year, mainly due to higher sales revenue, improved gross profit, and better control over operating expenses during the period.

Net Operating Cash Flow per Share (NOCFPS) declining from Tk. 0.03 to Tk. 0.02 compared to the corresponding period of the previous year, mainly due to higher operating cash payments to suppliers, employees, and other operating expenses during the period, despite improved cash collections from customers.

By order of the Board of Directors

-sd-

(Md. Mohi Uddin)

Company Secretary

The details of the published Second Quarter (Q2) Financial Statements are available in the website of the company: www.indo-banglapharma.com.